A detailed history of Geode Capital Management, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,806,106 shares of ADMA stock, worth $54.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,806,106
Previous 4,647,937 3.4%
Holding current value
$54.8 Million
Previous $21 Million 50.99%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$4.4 - $6.74 $695,943 - $1.07 Million
158,169 Added 3.4%
4,806,106 $31.7 Million
Q4 2023

Feb 13, 2024

BUY
$3.08 - $4.52 $912,677 - $1.34 Million
296,324 Added 6.81%
4,647,937 $21 Million
Q3 2023

Nov 13, 2023

BUY
$3.47 - $4.61 $619,905 - $823,562
178,647 Added 4.28%
4,351,613 $15.6 Million
Q2 2023

Aug 11, 2023

BUY
$3.12 - $4.22 $395,353 - $534,741
126,716 Added 3.13%
4,172,966 $15.4 Million
Q1 2023

May 15, 2023

BUY
$3.01 - $3.87 $1.98 Million - $2.55 Million
659,398 Added 19.47%
4,046,250 $13.4 Million
Q4 2022

Feb 13, 2023

BUY
$2.47 - $3.88 $248,785 - $390,805
100,723 Added 3.07%
3,386,852 $13.1 Million
Q3 2022

Nov 14, 2022

BUY
$2.03 - $2.86 $190,822 - $268,842
94,001 Added 2.94%
3,286,129 $7.99 Million
Q2 2022

Aug 12, 2022

BUY
$1.43 - $2.2 $2.11 Million - $3.24 Million
1,474,049 Added 85.8%
3,192,128 $6.32 Million
Q1 2022

May 13, 2022

BUY
$1.28 - $1.83 $389,829 - $557,333
304,554 Added 21.55%
1,718,079 $3.14 Million
Q4 2021

Feb 11, 2022

BUY
$1.09 - $1.66 $109,469 - $166,715
100,431 Added 7.65%
1,413,525 $1.99 Million
Q3 2021

Nov 12, 2021

BUY
$1.13 - $1.65 $293,536 - $428,615
259,767 Added 24.66%
1,313,094 $1.48 Million
Q2 2021

Aug 13, 2021

SELL
$1.51 - $2.07 $460,281 - $630,981
-304,822 Reduced 22.44%
1,053,327 $1.69 Million
Q1 2021

May 12, 2021

BUY
$1.67 - $2.95 $583,518 - $1.03 Million
349,412 Added 34.64%
1,358,149 $2.39 Million
Q4 2020

Feb 12, 2021

BUY
$1.8 - $2.56 $53,265 - $75,755
29,592 Added 3.02%
1,008,737 $1.97 Million
Q3 2020

Nov 13, 2020

SELL
$2.04 - $3.74 $224,094 - $410,839
-109,850 Reduced 10.09%
979,145 $2.34 Million
Q2 2020

Aug 13, 2020

SELL
$2.42 - $3.29 $108,873 - $148,013
-44,989 Reduced 3.97%
1,088,995 $3.19 Million
Q1 2020

May 14, 2020

BUY
$1.5 - $4.59 $626,064 - $1.92 Million
417,376 Added 58.24%
1,133,984 $3.27 Million
Q4 2019

Feb 13, 2020

BUY
$3.89 - $5.15 $366,103 - $484,687
94,114 Added 15.12%
716,608 $2.87 Million
Q3 2019

Nov 12, 2019

BUY
$3.19 - $5.39 $589,939 - $996,794
184,934 Added 42.26%
622,494 $2.77 Million
Q2 2019

Aug 14, 2019

BUY
$3.52 - $5.24 $406,127 - $604,575
115,377 Added 35.81%
437,560 $1.69 Million
Q1 2019

May 14, 2019

BUY
$2.61 - $4.35 $118,110 - $196,850
45,253 Added 16.34%
322,183 $1.22 Million
Q4 2018

Feb 13, 2019

BUY
$2.17 - $6.12 $75,555 - $213,086
34,818 Added 14.38%
276,930 $661,000
Q3 2018

Nov 13, 2018

BUY
$4.39 - $6.85 $179,998 - $280,863
41,002 Added 20.39%
242,112 $1.5 Million
Q2 2018

Aug 14, 2018

BUY
$4.39 - $5.44 $391,192 - $484,758
89,110 Added 79.56%
201,110 $907,000
Q4 2017

Feb 13, 2018

BUY
$2.06 - $3.24 $186,376 - $293,135
90,474 Added 420.3%
112,000 $359,000
Q2 2017

Aug 14, 2017

BUY
N/A
21,526
21,526 $82,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $2.24B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.